SEC Comment Letter 0000000000-24-007541 to Kiniksa Pharmaceuticals International, plc (KNSA) (CIK 0001730430) (KNSA)
Kiniksa Pharmaceuticals International, plc (KNSA) (CIK 0001730430)
Date: July 2, 2024 · CIK: 0001730430 · Accession: 0000000000-24-007541
AI Filing Summary & Sentiment
File numbers found in text: 333-280611
Letter
July 2, 2024 Sanj Patel Chief Executive Officer Kiniksa Pharmaceuticals International, plc 23 Old Bond Street, Floor 3 London, WIS 4PZ England, United Kingdom Re:Kiniksa Pharmaceuticals International, plc Registration Statement on Form S-3 Filed June 28, 2024 File No. 333-280611 Dear Sanj Patel: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Jason Drory at 202-551-8342 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc:Marko Zatylny
Show Raw Text
July 2, 2024
Sanj Patel
Chief Executive Officer
Kiniksa Pharmaceuticals International, plc
23 Old Bond Street, Floor 3
London, WIS 4PZ
England, United Kingdom
Re:Kiniksa Pharmaceuticals International, plc
Registration Statement on Form S-3
Filed June 28, 2024
File No. 333-280611
Dear Sanj Patel:
This is to advise you that we have not reviewed and will not review your registration
statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that
the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Jason Drory at 202-551-8342 with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc:Marko Zatylny